Eloralintide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 13 registered trials.

Why this status

  1. 15 Dec 2025: Trial registered, NCT07282600
  2. 15 Dec 2025: Trial started, NCT07282600
  3. 7 Jan 2026: Trial registered, NCT07321886
  4. 21 Jan 2026: Trial registered, NCT07353931
  5. 27 Jan 2026: Trial registered, NCT07369011
  6. 6 Feb 2026: Trial started, NCT07321886
  7. 9 Feb 2026: Trial started, NCT07353931
  8. 10 Feb 2026: Trial started, NCT07369011

The trials

NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

State
Completed
Phase
Phase 2
People
263 taking part
Started
5 Feb 2024
Primary completion
30 May 2025
Arms
1 mg Eloralintide, 3 mg Eloralintide, 6 mg Eloralintide, 9 mg Eloralintide, 6/9 mg Eloralintide, 3/6/9 mg Eloralintide
Results
Posted on the registry
Papers
doi:10.1016/s0140-6736(25)02155-5
  1. 30 Jan 2024: Trial registered
  2. 5 Feb 2024: Trial started
  3. 14 Aug 2025: Trial completed
  4. 24 Jun 2026: Trial results posted

NCT06297616: A Study of LY3841136 in Japanese Participants With Obesity or Overweight

State
Completed
Phase
Phase 1
People
128 taking part
Started
15 Apr 2024
Primary completion
21 Nov 2025
Arms
Part A: LY3841136, Part B: LY3841136 + Tirzepatide-Placebo
Results
None posted
  1. 7 Mar 2024: Trial registered
  2. 15 Apr 2024: Trial started
  3. 21 Nov 2025: Trial completed

NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

State
Completed
Phase
Phase 2
People
367 taking part
Started
20 Sep 2024
Primary completion
1 Jul 2026
Arms
LY3841136 Dose 1, LY3841136 Dose 2, LY3841136 Dose 3, LY3841136 Dose 1 + Tirzepatide Dose 1, LY3841136 Dose 2 + Tirzepatide Dose 1, LY3841136 Dose 2 + Tirzepatide Dose 2, LY3841136 Dose 3 + Tirzepatide Dose 3, LY3841136 Dose 2 + Tirzepatide Dose 3
Results
None posted
  1. 19 Sep 2024: Trial registered
  2. 20 Sep 2024: Trial started
  3. 14 Sep 2026: Trial completed

NCT06916065: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

State
Completed
Phase
Phase 1
People
188 taking part
Started
9 Apr 2025
Primary completion
19 Jan 2026
Arms
Eloralintide-Cohorts E and F
Results
None posted
  1. 8 Apr 2025: Trial registered
  2. 9 Apr 2025: Trial started
  3. 19 Jan 2026: Trial completed

NCT06916091: A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

State
Completed
Phase
Phase 1
People
30 taking part
Started
21 Apr 2025
Primary completion
9 Sep 2025
Arms
Eloralintide
Results
None posted
  1. 8 Apr 2025: Trial registered
  2. 21 Apr 2025: Trial started
  3. 9 Sep 2025: Trial completed

NCT07215559: A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

State
Under way
Phase
Phase 2
People
200 planned
Started
16 Oct 2025
Primary completion
Mar 2027
Arms
Eloralintide (Elorlintide + Macupatide Placebo)
Results
None posted
  1. 10 Oct 2025: Trial registered
  2. 16 Oct 2025: Trial started

NCT07282600: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

State
Under way
Phase
Phase 3
People
1,035 planned
Started
15 Dec 2025
Primary completion
Jan 2028
Arms
Eloralintide Dose 1, Eloralintide Dose 2, Eloralintide Dose 3, Eloralintide Dose 4
Results
None posted
  1. 15 Dec 2025: Trial registered
  2. 15 Dec 2025: Trial started

NCT07321886: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

State
Under way
Phase
Phase 3
People
1,980 planned
Started
6 Feb 2026
Primary completion
Mar 2028
Arms
Eloralintide Dose 1, Eloralintide Dose 2, Eloralintide Dose 3, Eloralintide Dose 4
Results
None posted
  1. 7 Jan 2026: Trial registered
  2. 6 Feb 2026: Trial started

NCT07353931: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

State
Under way
Phase
Phase 3
People
900 planned
Started
9 Feb 2026
Primary completion
Mar 2028
Arms
Eloralintide (YOA1), Eloralintide (YOA2)
Results
None posted
  1. 21 Jan 2026: Trial registered
  2. 9 Feb 2026: Trial started

NCT07369011: A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

State
Under way
Phase
Phase 3
People
800 planned
Started
10 Feb 2026
Primary completion
Mar 2028
Arms
Eloralintide (YSA1), Eloralintide (YSA2)
Results
None posted
  1. 27 Jan 2026: Trial registered
  2. 10 Feb 2026: Trial started

NCT07589608: A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

State
Under way
Phase
Phase 2
People
400 planned
Started
15 May 2026
Primary completion
Sep 2027
Arms
Eloralintide Dose 1, Eloralintide Dose 2, Eloralintide Dose 3
Results
None posted
  1. 15 May 2026: Trial registered
  2. 15 May 2026: Trial started

NCT07881432: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

State
Not started
Phase
Phase 3
People
2,115 planned
Started
Dec 2026
Primary completion
Oct 2029
Arms
Eloralintide
Results
None posted
  1. 19 Oct 2026: Trial registered

NCT07900633: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

State
Not started
Phase
Phase 3
People
3,000 planned
Started
Dec 2026
Primary completion
Nov 2029
Arms
Eloralintide
Results
None posted
  1. 28 Oct 2026: Trial registered

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.